Indigotindisulfonate: Difference between revisions
Rabin Bista (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |hasBlackBoxWarning=Yes |adverseReactions=<!--Black Box Warning--> |blackBoxWarningTitle=<span style="color:#FF0...") |
Rabin Bista (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
|authorTag={{RB}} | |||
|genericName=Indigotindisulfonate sodium | |||
|aOrAn=a | |aOrAn=a | ||
|indicationType= | |drugClass=Diagnostic Agent | ||
| | |indicationType=diagnosis | ||
|adverseReactions=<!--Black Box Warning--> | |indication=ureteral orifices during cystoscopy and ureteral catheterization | ||
|adverseReactions=allergic reaction | |||
<!--Black Box Warning--> | |||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | ||
<!--Adult Indications and Dosage--> | <!--Adult Indications and Dosage--> | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult====== | |fdaLIADAdult=====Indications==== | ||
Originally employed as a kidney function test, the chief application of Indigo Carmine at present is localizing ureteral orifices during cystoscopy and ureteral catheterization. | |||
====Dosage==== | |||
Indigo Carmine solution is injected either by the intravenous or intramuscular route, and its appearance at the ureteral orifices is watched with the cystoscope in place. The intravenous method is preferred because a 5 mL injection is sufficient. A lesser dosage in infants, children and underweight patients will prevent skin coloration. | |||
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. | |||
|offLabelAdultGuideSupport= | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
<!--Non–Guideline-Supported Use (Adult)--> | <!--Non–Guideline-Supported Use (Adult)--> | ||
|offLabelAdultNoGuideSupport= | |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
<!--Pediatric Indications and Dosage--> | <!--Pediatric Indications and Dosage--> | ||
<!--FDA-Labeled Indications and Dosage (Pediatric)--> | <!--FDA-Labeled Indications and Dosage (Pediatric)--> | ||
|fdaLIADPed= | |fdaLIADPed=* Safety and efficacy in pediatrics patients has not been established | ||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
* | |||
|offLabelPedGuideSupport= | |||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Non–Guideline-Supported Use (Pediatric)--> | <!--Non–Guideline-Supported Use (Pediatric)--> | ||
|offLabelPedNoGuideSupport= | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Contraindications--> | <!--Contraindications--> | ||
Line 314: | Line 245: | ||
<!--How Supplied--> | <!--How Supplied--> | ||
|howSupplied=* | |howSupplied=* | ||
|storage=Store at 20° to 25°C (68° to 77°F) | |||
|packLabel=<!--Patient Counseling Information--> | |packLabel=<!--Patient Counseling Information--> | ||
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. |
Revision as of 14:12, 23 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Indigotindisulfonate is a Diagnostic Agent that is FDA approved for the diagnosis of ureteral orifices during cystoscopy and ureteral catheterization. Common adverse reactions include allergic reaction.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
Originally employed as a kidney function test, the chief application of Indigo Carmine at present is localizing ureteral orifices during cystoscopy and ureteral catheterization.
Dosage
Indigo Carmine solution is injected either by the intravenous or intramuscular route, and its appearance at the ureteral orifices is watched with the cystoscope in place. The intravenous method is preferred because a 5 mL injection is sufficient. A lesser dosage in infants, children and underweight patients will prevent skin coloration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Indigotindisulfonate in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Indigotindisulfonate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- Safety and efficacy in pediatrics patients has not been established
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Indigotindisulfonate in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Indigotindisulfonate in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Indigotindisulfonate in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Indigotindisulfonate in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Indigotindisulfonate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Indigotindisulfonate during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Indigotindisulfonate with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Indigotindisulfonate with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Indigotindisulfonate with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Indigotindisulfonate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Indigotindisulfonate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Indigotindisulfonate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Indigotindisulfonate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Indigotindisulfonate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Indigotindisulfonate in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Indigotindisulfonate in the drug label.
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Indigotindisulfonate in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Indigotindisulfonate in the drug label.
Pharmacology
There is limited information regarding Indigotindisulfonate Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Indigotindisulfonate in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Indigotindisulfonate in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Indigotindisulfonate in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Indigotindisulfonate in the drug label.
How Supplied
Storage
Store at 20° to 25°C (68° to 77°F)
Images
Drug Images
{{#ask: Page Name::Indigotindisulfonate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Indigotindisulfonate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Indigotindisulfonate in the drug label.
Precautions with Alcohol
- Alcohol-Indigotindisulfonate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Indigotindisulfonate |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}} |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Indigotindisulfonate |Label Name=Indigotindisulfonate11.png
}}
{{#subobject:
|Label Page=Indigotindisulfonate |Label Name=Indigotindisulfonate11.png
}}